Literature DB >> 21040464

Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible.

D J Kubek1, D B Burr, M R Allen.   

Abstract

OBJECTIVE: The pathophysiology of osteonecrosis of the jaw (ONJ) is thought to be linked to suppression of intracortical remodeling. The aim of this study was to determine whether mice, which normally do not undergo appreciable amounts of intracortical remodeling, could be stimulated by ovariectomy to remodel within the cortex of the mandible and if bisphosphonates (BPs) would suppress this intracortical remodeling.
MATERIAL AND METHODS: Skeletally mature female C3H mice were either ovariectomized (OVX) or SHAM operated and treated with two intravenous doses of zoledronic acid (ZOL, 0.06 mg/kg body weight) or vehicle (VEH). This ZOL dose corresponds to the dose given to patients with cancer on a mg/kg basis, adjusted for body weight. Calcein was administered prior to sacrifice to label active formation sites. Dynamic histomorphometry of the mandible and femur was performed.
RESULTS: Vehicle-treated OVX animals had significantly higher (eightfold) intracortical remodeling of the alveolar portion of the mandible compared to sham--this was significantly suppressed by ZOL treatment. At all skeletal sites, overall bone formation rate was lower with ZOL treatment compared to the corresponding VEH group.
CONCLUSIONS: Under normal conditions, the level of intracortical remodeling in the mouse mandible is minimal but in C3H mice it can be stimulated to appreciable levels with ovariectomy. Based on this, if the suppression of intracortical remodeling is found to be part of the pathophysiology of ONJ, the ovariectomized C3H mouse could serve as a useful tool for studying this condition.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21040464      PMCID: PMC3051277          DOI: 10.1111/j.1601-6343.2010.01497.x

Source DB:  PubMed          Journal:  Orthod Craniofac Res        ISSN: 1601-6335            Impact factor:   1.826


  35 in total

1.  Animal models of osteonecrosis of the jaw.

Authors:  M R Allen
Journal:  J Musculoskelet Neuronal Interact       Date:  2007 Oct-Dec       Impact factor: 2.041

Review 2.  Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

3.  Zoledronic acid decreases bone formation without causing osteocyte death in mice.

Authors:  S S Huja; S A Fernandez; Christina Phillips; Y Li
Journal:  Arch Oral Biol       Date:  2009-07-09       Impact factor: 2.633

4.  Mandibular necrosis in beagle dogs treated with bisphosphonates.

Authors:  D B Burr; M R Allen
Journal:  Orthod Craniofac Res       Date:  2009-08       Impact factor: 1.826

Review 5.  Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench.

Authors:  Matthew R Allen
Journal:  Cells Tissues Organs       Date:  2008-08-13       Impact factor: 2.481

6.  Alveolar process anabolic activity in C3H/HeJ and C57BL/6J inbred mice.

Authors:  Isaac F Meta; Soledad A Fernandez; Parul Gulati; Sarandeep S Huja
Journal:  J Periodontol       Date:  2008-07       Impact factor: 6.993

Review 7.  The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.

Authors:  Matthew R Allen; David B Burr
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

8.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

9.  Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.

Authors:  Matthew R Allen; Susan Reinwald; David B Burr
Journal:  Calcif Tissue Int       Date:  2008-05-08       Impact factor: 4.333

10.  Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.

Authors:  Stephen T Sonis; Brynmor A Watkins; Gregory D Lyng; Mark A Lerman; Kenneth C Anderson
Journal:  Oral Oncol       Date:  2008-08-19       Impact factor: 5.337

View more
  16 in total

Review 1.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

2.  Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes.

Authors:  M W Aref; E M B McNerny; D Brown; K J Jepsen; M R Allen
Journal:  Osteoporos Int       Date:  2016-07-20       Impact factor: 4.507

3.  Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep.

Authors:  Pit J Voss; Martin J Stoddart; Anke Bernstein; Rainer Schmelzeisen; Katja Nelson; Vincent Stadelmann; Thomas Ziebart; Philipp J Poxleitner
Journal:  Clin Oral Investig       Date:  2015-04-07       Impact factor: 3.573

4.  Alendronate affects osteoblast functions by crosstalk through EphrinB1-EphB.

Authors:  E Shimizu; J Tamasi; N C Partridge
Journal:  J Dent Res       Date:  2011-12-15       Impact factor: 6.116

5.  Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.

Authors:  Shinichiro Kuroshima; Virginia-Arlene A Go; Junro Yamashita
Journal:  Endocrinology       Date:  2011-11-22       Impact factor: 4.736

6.  Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates.

Authors:  Sandra R Torres; Curtis S K Chen; Brian G Leroux; Peggy P Lee; Lars G Hollender; Michelle Lloid; Shane Patrick Drew; Mark M Schubert
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2015-02-14

7.  Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.

Authors:  Matthew R Allen; Neal X Chen; Vincent H Gattone; Sharon M Moe
Journal:  Am J Nephrol       Date:  2013-11-22       Impact factor: 3.754

8.  Bisphosphonate-induced reductions in rat femoral bone energy absorption and toughness are testing rate-dependent.

Authors:  Eric R Smith; Matthew R Allen
Journal:  J Orthop Res       Date:  2013-03-13       Impact factor: 3.494

9.  Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone.

Authors:  Matthew R Allen; Tien-Min Gabriel Chu; Salvatore L Ruggiero
Journal:  J Oral Maxillofac Surg       Date:  2013-02-01       Impact factor: 1.895

10.  The effect of bone morphometric changes on orthodontic tooth movement in an osteoporotic animal model.

Authors:  Megumi Hashimoto; Hitoshi Hotokezaka; Irin Sirisoontorn; Takako Nakano; Kotaro Arita; Motohiro Tanaka; Noriaki Yoshida
Journal:  Angle Orthod       Date:  2013-02-27       Impact factor: 2.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.